Novo Nordisk, Rose Pharmacy expand access to obesity care in Cebu
Novo Nordisk Philippines has partnered with Rose Pharmacy to strengthen obesity care and improve access to patient-centered weight management solutions in Cebu City and across the Visayas.
![]() |
| Novo Nordisk obesity care table at Rose Pharmacy Capitol Square Cebu City |
The collaboration aims to help address persistent barriers in obesity care, including limited awareness and stigma, while making it easier for people living with obesity to connect with trained healthcare professionals and access more seamless support throughout their treatment journey.
![]() |
| Wei Sun, General Manager of Novo Nordisk Philippines |
“Obesity is a chronic, complex disease that requires sustained care and support,” said Wei Sun, General Manager of Novo Nordisk Philippines. “By partnering with Rose Pharmacy, we hope to help more Filipinos in Cebu and nearby communities access the right treatment and long-term care they deserve.”
Through Rose Pharmacy’s trusted retail network, patients will gain greater awareness of obesity as a medical condition and benefit from more convenient access to science-based, patient-centered care.
![]() |
| Michael So, General Manager of Rose Pharmacy and Wei Sun, General Manager of Novo Nordisk Philippines |
“We believe pharmacies play an important role in helping patients take the first step toward better health,” said --- Michael So, General Manager of Rose Pharmacy. “By working with Novo Nordisk, we hope to make it easier for more Cebuanos to access reliable information and the support they need to manage obesity with confidence and dignity.”
![]() |
| Rose Pharmacy Capitol Square Cebu City |
This partnership forms part of Novo Nordisk’s broader Live Lighter movement, which aims to improve how obesity is understood and treated in the Philippines. As part of these efforts, Novo Nordisk continues to expand partnerships that integrate clinical expertise, patient support, and innovation, complemented by science-based treatments such as semaglutide-based GLP-1 receptor agonist therapies—helping more Filipinos live lighter, healthier lives.
.jpg)
.jpg)
.jpg)
.jpg)



.jpg)
.jpg)